Journal Article Corrected proof Insights in Dolutegravir-Resistance Pathways Get access Thibault Mesplede, Thibault Mesplede Viroscience Department, Erasmus Medical Center, Rotterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Pierre Gantner Pierre Gantner Clinical Virology Laboratory, Strasbourg University Hospital, Strasbourg, FranceINSERM UMR_S1109, Strasbourg University, Strasbourg, France Correspondence: P. Gantner, Institut de Virologie, 3 rue Koeberlé, F67000 Strasbourg, France (pierre.gantner@chru-strasbourg.fr). https://orcid.org/0000-0002-3984-883X Search for other works by this author on: Oxford Academic PubMed Google Scholar Clinical Infectious Diseases, ciae127, https://doi.org/10.1093/cid/ciae127 Published: 11 March 2024 Article history Published: 11 March 2024 Corrected and typeset: 30 March 2024
No takes yet. Share an insight, caveat, or question.
Mésplède et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: